The global viral vector development market is expected to enjoy a valuation of US$ 730.7 Million by the end of the year 2023, and further expand at a CAGR of 18.7% to reach a valuation of US$ 4.1 Billion by the year 2033. According to the recent study by Future Market Insights, adeno-associated viral vectors (AAV) are leading the market with an expected share of about 37.0% in the year 2023, within the global market.
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 624.7 Million |
| Market Value 2023 | US$ 730.7 Million |
| Market Value 2033 | US$ 4.1 Billion |
| CAGR 2023 to 2033 | 18.7% |
| Market Share of Top 5 Countries | 57.5% |
| Key Market Players List | Thermo Fisher Scientific Inc; Charles River (Cobra Biologics); NOVASEP; uniQure N.V; Waisman Biomanufacturing; Creative Biogene; GenScript Biotech Corporation; Novartis AG ; Merck KGaA; Takara Bio, Inc.; FUJIFILM Diosynth Biotechnologies; LONZA; Danaher Corp. (Aldevron); Sirion Biotech GmbH; and AGC Biologics |
Since viral vectors are created utilising animal cell cultures, and in some cases insect cell cultures, they are essentially made from viruses which naturally infect human or other mammalian cells. The last ten years have seen a tremendous advancement in manufacturing techniques for the development of clinical grade viral vectors. This is crucial for gene therapy methods implemented to the treatment of congenital or acquired disorders. AAV and lentiviral vectors are currently being used more frequently for in vivo and ex vivo gene delivery, respectively.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market value for viral vector development was approximately 35.5% of the overall ~US$ 30.86 Million of the global cancer gene therapy market in 2022.
The sale of viral vector development expanded at a CAGR of 14.5% from 2017 to 2022.
Traditional medicine researchers and the medical world have long believed that hereditary disorders are incurable. Genetic therapy, on the other hand, heralded a new era in medicine by offering the chance to fix the damaged genes that cause certain inherited illnesses.
Adeno-associated virus, often known as AAV, is frequently utilised as a carrier in the gene therapy procedure. The products made with viral vectors are proving to be suitable for the market because gene therapy has numerous potential applications in the medical sciences. Many biopharmaceutical companies are engaged in manufacturing and supply, which could be aimed at balancing the demand-supply ratio.
Despite the unexpected disruption of the world economy for all products during the pandemic years that followed the outbreak of COVID-19 infections, it offered tremendous chances for the viral vector CDMO business to expand globally. The search for a therapeutic approach and a vaccine to prevent the causal pathogen's rapid spread involved numerous research centres and private biopharmaceutical businesses.
It was necessary to cultivate a novel coronavirus in order to build any kind of countermeasure, which raised the need for viral vector products. Private manufacturing firms and public institutions developing viral vectors drove the production and supply of all varieties of viral vectors, including recombinant adenoviral vectors.
The AAV-based vaccine for COVID-19 infection prevention is currently been developed by a number of businesses and state organisations. The global viral vector market will be driven by the COVID-19, which is the subject of extensive research to produce a more effective vaccination for the upcoming years. Thus, owing to the aforementioned factors, the global viral vector development market is expected to grow at a CAGR of 18.7% during the forecast period between 2023 and 2033.
H1-H2 Update
| Market Statistics | Details |
|---|---|
| Jan - Jun (H1), 2021 (A) | 13.21% |
| Jul - Dec (H2), 2021 (A) | 16.95% |
| Jan - Jun (H1),2022 Projected (P) | 13.65% |
| Jan - Jun (H1),2022 Outlook (O) | 14.28% |
| Jul - Dec (H2), 2022 Outlook (O) | 17.66% |
| Jul - Dec (H2), 2022 Projected (P) | 16.92% |
| Jan - Jun (H1), 2023 Projected (P) | 15.08% |
| BPS Change : H1,2022 (O) - H1,2022 (P) | 63↑ |
| BPS Change : H1,2022 (O) - H1,2021 (A) | 107↑ |
| BPS Change: H2, 2022 (O) - H2, 2022 (P) | 74↑ |
| BPS Change: H2, 2022 (O) - H2, 2021 (A) | 71↑ |
Gene therapy is necessary to repair suppressed and malfunctioning genes in human cells or tissues and return the abnormality to normal levels. Viral vector technology is used to cultivate the gene, and this business has grown significantly for many private players. For the most part, two different types of techniques are used to use viral vectors in the gene therapy-induced healing process.
When it comes to 2D planer technologies, scaling out of adherent cell systems is a common strategy that has been applied up until the point of market analysis. The production of suspension AAV by diverse segments will, therefore, rely increasingly on 3D suspension cell cultures or bioreactors in the upcoming period.
The synthesis of viral vectors using cell culture technology has been successfully modified to satisfy the demands of both early and advanced clinical trial phases. Scale-up, however, may still be constrained depending on the vector type and the cell culture production platforms chosen.
Presently, great progress is being made in the generation of cell lines that can create inducible or constitutively expressed lentiviral vectors that grow in suspension. Recently, the first batch of lentiviral vectors generated by reliable producer cell lines was utilised in a clinical trial setting.
With extensive safety and efficacy data gathered from various clinical trials, it is evident that gene therapy is making great progress. These factors are set to promote the expansion of the global market, over the forecast period.
Principal Consultant
The deployment of exceedingly complex procedures was brought about by the need for clinical-grade, thoroughly polished final products. For the initial set of production units, such advanced technological techniques require a significant investment from the viral vector firms.
The primary barrier to the rapid development of viral vectors for varied purposes remains the strict government requirements for sanctioning any new development related to the healthcare sector.
The global viral vector development market's expansion is undoubtedly constrained by the lack of enough good laboratories for the testing and approval of essential raw materials.
Due to its superior safety profile and effective transduction to a variety of target tissues, adeno-associated virus (AAV) has become a major platform for the delivery of genes for the treatment of many disorders. Viral vectors are less effective than recombinant protein treatments in large-scale production and long-term preservation, which results in lower yields, a modest level of purity, and a shorter shelf life.
The cost-effective manufacture of viral vectors remains a challenge despite notable clinical and commercial accomplishments, primarily because it is unclear how different methods affect the quality and shelf-life of AAV products.
This is because AAV gene therapy's clinical progress has outpaced its CMC, manufacturing, and formulation development. These factors are expected to restrain the market expansion over the forecast period.
| Country | The USA |
|---|---|
| Market Share (2023) | 33.5% |
| Market Share (2033) | 31.8% |
| BPS Analysis | -169 |
| Country | China |
|---|---|
| Market Share (2023) | 6.7% |
| Market Share (2033) | 4.2% |
| BPS Analysis | -245 |
| Country | UK |
|---|---|
| Market Share (2023) | 6.4% |
| Market Share (2033) | 7.1% |
| BPS Analysis | 63 |
| Country | Germany |
|---|---|
| Market Share (2023) | 5.8% |
| Market Share (2033) | 7.6% |
| BPS Analysis | 177 |
| Country | Japan |
|---|---|
| Market Share (2023) | 4.8% |
| Market Share (2033) | 2.7% |
| BPS Analysis | -208 |
The USA dominates the globe with a total market share of about 33.1% in 2022, and is expected to continue to experience the same growth throughout the forecast period.
One of the key reasons fueling the market's growth throughout the forecast period is the rising number of patients choosing gene therapy to treat diseases like hemophilia, heart disease, diabetes, cystic fibrosis, cancer, and AIDS. The increased development of gene therapy has increased the demand for plasmid DNA. Collaborations between businesses, various organizations, academic institutions, and nonprofit groups are growing as they work to create viral vectors and plasmid DNA. These elements encourage market expansion in the United States.
Germany held a market share of nearly 5.6% in the global viral vector development market in 2022.
In February 2020, the US production facility of the German-based viral vector company Vibalogics, CDMO was established. By providing CDMO viral vector, this facility in Massachusetts that was developed with a $150 million investment, is anticipated to seize the North American market. With such expansions taking place among the key players into developing regions, the market is set to expand in Germany
China held a share of around 7.1% in the global market, in 2022.
In order to increase its capabilities and production capacity, VectorBuilder stated in April 2022 that it would build a $500 million gene delivery and research facility in Guangzhou, China.
The "Gene Delivery Research and Manufacturing Campus," as it has been dubbed by contract development manufacturing organization (CDMO) VectorBuilder, which offers gene delivery systems, will be constructed over the course of four years.
The campus will have 30 production suites, according to the company, that can produce plasmids, cell lines, adeno-associated virus (AAV), lentivirus, messenger RNA (mRNA), and other viral and non-viral vectors.
Such advancements within the country are expected to propel the growth of the overall market throughout the forecast period.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Adeno-associated viral vectors are set to hold a share of around 37.0% in the global market, in 2023.
Adeno-associated viral vectors are the most efficient way to transfer genes to treat a wide range of human illnesses. Recent advancements in the design of therapeutically appealing AAV capsids, genome optimization, and the use of advanced biotechnologies have resulted in a considerable expansion of the area of gene therapy. Two AAV-based drugs have been approved by regulators in the US or Europe, proving the clinical and preclinical efficacy of AAV as the ideal therapeutic vector for gene editing, gene silencing, and gene substitution.
The stable expression system will hold a global market share of around 85.80% in 2023.
Owing of its intricacy, viral vector manufacturing is still evolving. The majority of researchers acknowledge that obtaining sufficient yields of functional capsids with the required genetic payload represents the biggest challenge. The most commonly used strategy is transient transfection, which effectively creates a cell line for every production cycle or a "cell factory" for a single production cycle. A stable and optimised manufacturing cell line, analogous to the ones used for other biologics, would provide a more reliable approach and be scalable if cells were cultured in suspension. Over the anticipated years, this is expected to increase the segment value.
Gene therapy applications are set to hold a market share of around 55.1% in the global market in 2023.
Because viruses have proven to be particularly effective at entering cells, vectors are frequently created from them. All viral genes are removed from vectors before they are changed to solely carry therapeutic genes, making them safe to employ. Three different types of vectors—adeno-associated virus (AAV) vectors, adenovirus vectors, or lentivirus vectors—are used by almost all gene therapies currently on the market.
Viral vectors are used in gene therapy to address more than just symptoms. With the genetic information they contain, vectors can modify a cell's behavior and target the underlying cause of a disease. They are frequently used for uncommon genetic disorders for whom there are few to no other effective treatments, and they normally only need to be delivered once.
Academic and Research Institutes are set to hold a significant market share of around 45.7% globally, in 2023.
According to data provided by the WHO and FDA, by February 2022, there were 114 candidate vaccines in clinical trials, 75 animal preclinical trials, and 14 vaccinations that have been licensed for emergency use. In order to develop drug candidates more efficiently, with enhanced therapeutic potential and greater access for patients worldwide, there has been a surge in collaborations between pharmaceutical companies and academic and research institutes, thus propelling segment growth within the overall market.
The market for the production of plasmid DNA and viral vector CDMO has become extremely competitive in recent years as a result of the introduction of numerous companies in these industries. The main tactic used by the leading firms to stay ahead of their rivals is the expansion of production facilities. A cost-effective strategy for the rapid expansion and capacity building for viral vector process development for the manufacturers is the acquisition of small regional companies.
Recent Market Developments
Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the viral vector development market, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2017 to 2022 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Türkiye, GCC Countries, North Africa, and South Africa |
| Key Market Segments Covered | Virus, Application, Expression System, End User, and Region |
| Key Companies Covered | Thermo Fisher Scientific Inc; Charles River (Cobra Biologics); NOVASEP; uniQure N.V; Waisman Biomanufacturing; Creative Biogene; GenScript Biotech Corporation; Novartis AG; Merck KGaA; Takara Bio, Inc.; FUJIFILM Diosynth Biotechnologies; LONZA; Danaher Corp. (Aldevron); Sirion Biotech GmbH; AGC Biologics |
| Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
| Pricing | Available upon Request |
The viral vector development market is pegged at a value of US$ 730.7 million in 2023.
The viral vector development market is estimated to reach US$ 4.1 billion by 2033.
Sales of viral vector development are anticipated to surge at a noteworthy CAGR of 18.7% through 2033.
The United States has turned into a key hub in the market with a sizeable share of 33.1% in 2022.
The viral vector development market reached a value of US$ 624.7 million In 2022.
1. Executive Summary | Viral Vector Development Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Market Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology, by Region
4.2. Technological Assessment
4.3. Regulatory Landscape
4.4. Promotional Strategies, By Key Players
4.5. PESTEL Analysis
4.6. Porter’s Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Outlook
5.1.3. Global Cancer Gene Therapy Market Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Prevalence of Chronic Diseases
5.2.2. Increasing Research and Development in Oncology Gene Therapy
5.2.3. Rising Investments in Viral Gene Therapy
5.2.4. New Product Launch Activities
5.2.5. Technological Advancements
5.2.6. Regulatory Impositions
5.2.7. Growing CMO/CDMO Activities
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Virus
6.1.2. By Expression System
6.1.3. By Application
6.1.4. By End User
6.1.5. By Country
6.2. 2022 Market Scenario
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
7.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
7.2. Current and Future Market Size (US$ Million) Analysis and Forecast, 2023 to 2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Virus
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Virus, 2017 to 2022
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Virus, 2023 to 2033
8.3.1. Lentiviral Vectors
8.3.2. Adenoviral Vectors
8.3.3. Adeno-Associated Viral Vectors
8.3.4. Retrovirus
8.4. Market Attractiveness Analysis By Virus
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Expression System
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis, By Expression System, 2017 to 2022
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Expression System, 2023 to 2033
9.3.1. Transient
9.3.2. Stable
9.4. Market Attractiveness Analysis By Expression System
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Application
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis By Application, 2017 to 2022
10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033
10.3.1. Gene Therapy
10.3.2. Vaccines
10.3.3. Cancer Therapy
10.3.4. Others
10.4. Market Attractiveness Analysis By Application
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Million) Analysis, By End User, 2017 to 2022
11.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2023 to 2033
11.3.1. Biotechnology Companies
11.3.2. Pharmaceutical Companies
11.3.3. Contract Research Organization (CRO)
11.3.4. Academic and Research Institutes
11.4. Market Attractiveness Analysis By End User
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
13.3.1. By Country
13.3.1.1. USA
13.3.1.2. Canada
13.3.2. By Virus
13.3.3. By Expression System
13.3.4. By Application
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Virus
13.4.3. By Expression System
13.4.4. By Application
13.4.5. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. USA Market Analysis
13.8.1.1. .Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Virus
13.8.1.2.2. By Expression System
13.8.1.2.3. By Application
13.8.1.2.4. By End User
13.8.2. Canada Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Virus
13.8.2.2.2. By Expression System
13.8.2.2.3. By Application
13.8.2.2.4. By End User
14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Virus
14.3.3. By Expression System
14.3.4. By Application
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Virus
14.4.3. By Expression System
14.4.4. By Application
14.4.5. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Mexico Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Virus
14.8.1.2.2. By Expression System
14.8.1.2.3. By Application
14.8.1.2.4. By End User
14.8.2. Brazil Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Virus
14.8.2.2.2. By Expression System
14.8.2.2.3. By Application
14.8.2.2.4. By End User
14.8.3. Argentina Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Virus
14.8.3.2.2. By Expression System
14.8.3.2.3. By Application
14.8.3.2.4. By End User
15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
15.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. United Kingdom
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Virus
15.3.3. By Expression System
15.3.4. By Application
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Virus
15.4.3. By Expression System
15.4.4. By Application
15.4.5. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Virus
15.8.1.2.2. By Expression System
15.8.1.2.3. By Application
15.8.1.2.4. By End User
15.8.2. Italy Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. B By Virus
15.8.2.2.2. By Expression System
15.8.2.2.3. By Application
15.8.2.2.4. By End User
15.8.3. France Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Virus
15.8.3.2.2. By Expression System
15.8.3.2.3. By Application
15.8.3.2.4. By End User
15.8.4. United Kingdom Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Virus
15.8.4.2.2. By Expression System
15.8.4.2.3. By Application
15.8.4.2.4. By End User
15.8.5. Spain Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Virus
15.8.5.2.2. By Expression System
15.8.5.2.3. By Application
15.8.5.2.4. By End User
15.8.6. BENELUX Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Virus
15.8.6.2.2. By Expression System
15.8.6.2.3. By Application
15.8.6.2.4. By End User
15.8.7. Russia Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Virus
15.8.7.2.2. By Expression System
15.8.7.2.3. By Application
15.8.7.2.4. By End User
16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Virus
16.3.3. By Expression System
16.3.4. By Application
16.3.5. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Virus
16.4.3. By Expression System
16.4.4. By Application
16.4.5. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Virus
16.8.1.2.2. By Expression System
16.8.1.2.3. By Application
16.8.1.2.4. By End User
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Virus
16.8.2.2.2. By Expression System
16.8.2.2.3. By Application
16.8.2.2.4. By End User
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Virus
16.8.3.2.2. By Expression System
16.8.3.2.3. By Application
16.8.3.2.4. By End User
17. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
17.3.1. By Country
17.3.1.1. India
17.3.1.2. Indonesia
17.3.1.3. Malaysia
17.3.1.4. Thailand
17.3.1.5. Rest of South Asia
17.3.2. By Virus
17.3.3. By Expression System
17.3.4. By Application
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Virus
17.4.3. By Expression System
17.4.4. By Application
17.4.5. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. India Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Virus
17.8.1.2.2. By Expression System
17.8.1.2.3. By Application
17.8.1.2.4. By End User
17.8.2. Indonesia Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Virus
17.8.2.2.2. By Expression System
17.8.2.2.3. By Application
17.8.2.2.4. By End User
17.8.3. Malaysia Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Virus
17.8.3.2.2. By Expression System
17.8.3.2.3. By Application
17.8.3.2.4. By End User
17.8.4. Thailand Market Analysis
17.8.4.1. Introduction
17.8.4.2. Market Analysis and Forecast by Market Taxonomy
17.8.4.2.1. By Virus
17.8.4.2.2. By Expression System
17.8.4.2.3. By Application
17.8.4.2.4. By End User
18. Oceania Market 2017 to 2022 and Forecast 2023 to 2033
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
18.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Virus
18.3.3. By Expression System
18.3.4. By Application
18.3.5. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Virus
18.4.3. By Expression System
18.4.4. By Application
18.4.5. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Virus
18.8.1.2.2. By Expression System
18.8.1.2.3. By Application
18.8.1.2.4. By End User
18.8.2. New Zealand Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Virus
18.8.2.2.2. By Expression System
18.8.2.2.3. By Application
18.8.2.2.4. By End User
19. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033
19.1. Introduction
19.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2017 to 2022
19.3. Current and Future Market Size (US$ Million) Analysis and Forecast by Market Taxonomy, 2023 to 2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Türkiye
19.3.1.3. North Africa
19.3.1.4. South Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Virus
19.3.3. By Expression System
19.3.4. By Application
19.3.5. By End User
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Virus
19.4.3. By Expression System
19.4.4. By Application
19.4.5. By End User
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Virus
19.8.1.2.2. By Expression System
19.8.1.2.3. By Application
19.8.1.2.4. By End User
19.8.2. Türkiye Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Virus
19.8.2.2.2. By Expression System
19.8.2.2.3. By Application
19.8.2.2.4. By End User
19.8.3. South Africa Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Virus
19.8.3.2.2. By Expression System
19.8.3.2.3. By Application
19.8.3.2.4. By End User
19.8.4. North Africa Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Virus
19.8.4.2.2. By Expression System
19.8.4.2.3. By Application
19.8.4.2.4. By End User
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. Thermo Fisher Scientific Inc
21.3.1.1. Overview
21.3.1.2. Product Overview
21.3.1.3. Sales Footprint
21.3.1.4. Key Financials
21.3.1.5. SWOT Analysis
21.3.1.6. Strategy Overview
21.3.1.6.1. Marketing Strategy
21.3.1.6.2. Product Strategy
21.3.1.6.3. Channel Strategy
21.3.2. Charles River (Cobra Biologics)
21.3.2.1. Overview
21.3.2.2. Product Overview
21.3.2.3. Sales Footprint
21.3.2.4. Key Financials
21.3.2.5. SWOT Analysis
21.3.2.6. Strategy Overview
21.3.2.6.1. Marketing Strategy
21.3.2.6.2. Product Strategy
21.3.2.6.3. Channel Strategy
21.3.3. NOVASEP
21.3.3.1. Overview
21.3.3.2. Product Overview
21.3.3.3. Sales Footprint
21.3.3.4. Key Financials
21.3.3.5. SWOT Analysis
21.3.3.6. Strategy Overview
21.3.3.6.1. Marketing Strategy
21.3.3.6.2. Product Strategy
21.3.3.6.3. Channel Strategy
21.3.4. uniQure N.V
21.3.4.1. Overview
21.3.4.2. Product Overview
21.3.4.3. Sales Footprint
21.3.4.4. Key Financials
21.3.4.5. SWOT Analysis
21.3.4.6. Strategy Overview
21.3.4.6.1. Marketing Strategy
21.3.4.6.2. Product Strategy
21.3.4.6.3. Channel Strategy
21.3.5. Waisman Biomanufacturing
21.3.5.1. Overview
21.3.5.2. Product Overview
21.3.5.3. Sales Footprint
21.3.5.4. Key Financials
21.3.5.5. SWOT Analysis
21.3.5.6. Strategy Overview
21.3.5.6.1. Marketing Strategy
21.3.5.6.2. Product Strategy
21.3.5.6.3. Channel Strategy
21.3.6. Creative Biogene
21.3.6.1. Overview
21.3.6.2. Product Overview
21.3.6.3. Sales Footprint
21.3.6.4. Key Financials
21.3.6.5. SWOT Analysis
21.3.6.6. Strategy Overview
21.3.6.6.1. Marketing Strategy
21.3.6.6.2. Product Strategy
21.3.6.6.3. Channel Strategy
21.3.7. GenScript Biotech Corporation
21.3.7.1. Overview
21.3.7.2. Product Overview
21.3.7.3. Sales Footprint
21.3.7.4. Key Financials
21.3.7.5. SWOT Analysis
21.3.7.6. Strategy Overview
21.3.7.6.1. Marketing Strategy
21.3.7.6.2. Product Strategy
21.3.7.6.3. Channel Strategy
21.3.8. Novartis AG
21.3.8.1. Overview
21.3.8.2. Product Overview
21.3.8.3. Sales Footprint
21.3.8.4. Key Financials
21.3.8.5. SWOT Analysis
21.3.8.6. Strategy Overview
21.3.8.6.1. Marketing Strategy
21.3.8.6.2. Product Strategy
21.3.8.6.3. Channel Strategy
21.3.9. Merck KGaA
21.3.9.1. Overview
21.3.9.2. Product Overview
21.3.9.3. Sales Footprint
21.3.9.4. Key Financials
21.3.9.5. SWOT Analysis
21.3.9.6. Strategy Overview
21.3.9.6.1. Marketing Strategy
21.3.9.6.2. Product Strategy
21.3.9.6.3. Channel Strategy
21.3.10. Takara Bio, Inc.
21.3.10.1. Overview
21.3.10.2. Product Overview
21.3.10.3. Sales Footprint
21.3.10.4. Key Financials
21.3.10.5. SWOT Analysis
21.3.10.6. Strategy Overview
21.3.10.6.1. Marketing Strategy
21.3.10.6.2. Product Strategy
21.3.10.6.3. Channel Strategy
21.3.11. FUJIFILM Diosynth Biotechnologies
21.3.11.1. Overview
21.3.11.2. Product Overview
21.3.11.3. Sales Footprint
21.3.11.4. Key Financials
21.3.11.5. SWOT Analysis
21.3.11.6. Strategy Overview
21.3.11.6.1. Marketing Strategy
21.3.11.6.2. Product Strategy
21.3.11.6.3. Channel Strategy
21.3.12. LONZA
21.3.12.1. Overview
21.3.12.2. Product Overview
21.3.12.3. Sales Footprint
21.3.12.4. Key Financials
21.3.12.5. SWOT Analysis
21.3.12.6. Strategy Overview
21.3.12.6.1. Marketing Strategy
21.3.12.6.2. Product Strategy
21.3.12.6.3. Channel Strategy
21.3.13. Danaher Corp. (Aldevron)
21.3.13.1. Overview
21.3.13.2. Product Overview
21.3.13.3. Sales Footprint
21.3.13.4. Key Financials
21.3.13.5. SWOT Analysis
21.3.13.6. Strategy Overview
21.3.13.6.1. Marketing Strategy
21.3.13.6.2. Product Strategy
21.3.13.6.3. Channel Strategy
21.3.14. Sirion Biotech GmbH
21.3.14.1. Overview
21.3.14.2. Product Overview
21.3.14.3. Sales Footprint
21.3.14.4. Key Financials
21.3.14.5. SWOT Analysis
21.3.14.6. Strategy Overview
21.3.14.6.1. Marketing Strategy
21.3.14.6.2. Product Strategy
21.3.14.6.3. Channel Strategy
21.3.15. AGC Biologics
21.3.15.1. Overview
21.3.15.2. Product Overview
21.3.15.3. Sales Footprint
21.3.15.4. Key Financials
21.3.15.5. SWOT Analysis
21.3.15.6. Strategy Overview
21.3.15.6.1. Marketing Strategy
21.3.15.6.2. Product Strategy
21.3.15.6.3. Channel Strategy
22. Assumptions and Acronyms Used
23. Research Methodology
Explore Healthcare Insights
View Reports
Viral Vector Development Market
